4//SEC Filing
Sweeny Nicole 4
Accession 0001827505-25-000004
CIK 0001348911other
Filed
Dec 3, 7:00 PM ET
Accepted
Dec 4, 4:02 PM ET
Size
13.0 KB
Accession
0001827505-25-000004
Insider Transaction Report
Form 4
Sweeny Nicole
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-11-21+6,250→ 38,541 total - Exercise/Conversion
Common Stock
2025-11-22+5,000→ 43,541 total - Sale
Common Stock
2025-11-24$13.45/sh−3,813$51,289→ 39,728 total - Exercise/Conversion
Restricted Stock Unit
2025-11-21−6,250→ 81,250 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-11-22−5,000→ 50,000 total→ Common Stock (5,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.
Documents
Issuer
KalVista Pharmaceuticals, Inc.
CIK 0001348911
Entity typeother
Related Parties
1- filerCIK 0001827505
Filing Metadata
- Form type
- 4
- Filed
- Dec 3, 7:00 PM ET
- Accepted
- Dec 4, 4:02 PM ET
- Size
- 13.0 KB